Bridgeway Capital Management LLC Buys 109,800 Shares of Biodesix, Inc. (NASDAQ:BDSX)

Bridgeway Capital Management LLC lifted its position in Biodesix, Inc. (NASDAQ:BDSX) by 38.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 394,311 shares of the company’s stock after buying an additional 109,800 shares during the quarter. Bridgeway Capital Management LLC’s holdings in Biodesix were worth $603,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of BDSX. AIGH Capital Management LLC lifted its stake in Biodesix by 8.8% in the 4th quarter. AIGH Capital Management LLC now owns 6,179,812 shares of the company’s stock worth $9,455,000 after purchasing an additional 500,000 shares in the last quarter. Birchview Capital LP increased its holdings in shares of Biodesix by 0.7% in the fourth quarter. Birchview Capital LP now owns 5,581,176 shares of the company’s stock worth $8,539,000 after purchasing an additional 40,000 shares during the period. Silverarc Capital Management LLC raised its position in shares of Biodesix by 21.7% in the fourth quarter. Silverarc Capital Management LLC now owns 4,332,281 shares of the company’s stock worth $6,628,000 after buying an additional 771,187 shares in the last quarter. Samjo Management LLC bought a new stake in Biodesix during the fourth quarter valued at $3,790,000. Finally, Susquehanna International Group LLP grew its position in Biodesix by 769.8% during the fourth quarter. Susquehanna International Group LLP now owns 1,115,748 shares of the company’s stock worth $1,707,000 after buying an additional 987,475 shares in the last quarter. Hedge funds and other institutional investors own 20.96% of the company’s stock.

Biodesix Stock Up 8.9%

Shares of BDSX opened at $0.38 on Monday. Biodesix, Inc. has a 1 year low of $0.34 and a 1 year high of $2.04. The company has a debt-to-equity ratio of 1.30, a current ratio of 3.40 and a quick ratio of 3.40. The stock has a 50 day simple moving average of $0.63 and a two-hundred day simple moving average of $1.02. The firm has a market cap of $55.46 million, a P/E ratio of -0.97 and a beta of 1.18.

Biodesix (NASDAQ:BDSX) last released its earnings results on Monday, March 3rd. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.01. The company had revenue of $20.43 million for the quarter, compared to analyst estimates of $19.92 million. Biodesix had a negative net margin of 66.84% and a negative return on equity of 275.79%. On average, analysts forecast that Biodesix, Inc. will post -0.35 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Scott Hutton sold 83,660 shares of the stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $0.92, for a total transaction of $76,967.20. Following the completion of the sale, the chief executive officer now directly owns 701,947 shares in the company, valued at $645,791.24. This represents a 10.65% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Over the last three months, insiders have sold 128,702 shares of company stock valued at $118,406. 69.20% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several research firms have weighed in on BDSX. Canaccord Genuity Group lowered their price target on Biodesix from $3.50 to $2.50 and set a “buy” rating on the stock in a report on Tuesday, April 29th. William Blair reiterated an “outperform” rating on shares of Biodesix in a research report on Tuesday, March 4th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $2.83.

About Biodesix

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.